- Conduit Pharmaceuticals has partnered with Agility Life Sciences, a formulation development CDMO, to create advanced oral-dosage forms for its autoimmune pipeline.
- The collaboration focuses on proprietary solid forms protected by composition-of-matter intellectual property, aiming to optimise clinical and market outcomes.
Conduit Pharmaceuticals Inc. has entered into a strategic services agreement with Agility Life Sciences, a formulation development contract development and manufacturing organisation (CDMO). The partnership focuses on developing new oral-dosage formulations for Conduit’s autoimmune pipeline, leveraging Agility’s expertise to support future clinical trials.
Conduit has developed novel and advantageous solid forms for its autoimmune assets, each protected by new composition-of-matter intellectual property (IP). Through its collaboration with Agility, the company aims to transform these proprietary forms into enhanced oral formulations. These new formulations are being designed with patient preferences and disease-specific needs in mind to maximise their market potential while maintaining robust IP protection.
Conduit’s strategy includes acquiring Phase 2-ready assets, several of which already feature clinically tested oral formulations. This allows the company to streamline its transition into Phase 2 trials using existing data packages. Alongside its ongoing clinical trial plans, Conduit will work with Agility on proprietary enhancements to its formulations.
The dual-track approach enables to advance clinical trials efficiently while optimising the market positioning of each asset. This strategy is expected to enhance market protection, improve asset value, and strengthen future licensing opportunities.